Hyaline membrane disease (HMD) therapy in Latin America: Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources

Jose Diaz Rossello, Paul Estol Hayward, Miguel Martell, Mario Del Barco, Paulo Margotto, Jose Grandzoto, Jaime Bastida, Jose L. Pena, Dina Villanueva

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Impact of surfactant administration, on neonatal mortality, morbidity and resource use, was assayed in a historically controlled study in 19 NICUs from 5 Latin American countries. Data from clinical records of infants with HMD were retrospectively reviewed for the previous 2 years (PRE phase n = 666 cases), and prospectively in cases that received surfactant (SURF phase, 348 cases). Birth weight stratified relative risk, with 95% confidence interval (RR ± 95% CI) for death, in the SURF as compared to the PRE was 0.60 (0.49-0.74), 0.79 (0.68-0.92) and 0.82 (0.71-0.94), for days 7, 28 and at discharge, respectively. At all ages mortality was significantly lower during SURF. Significant increases were observed in the occurrence of pulmonary interstitial emphysema, pulmonary hemorrhage, patent ductus arteriosus, bronchopulmonary dysplasia, intrahospital infection and necrotizing enterocolitis. Resource use increased significantly. It is concluded that the use of surfactant in the region is an important advance, and the efficacy of management of the late complications of the very premature and labile HMD survivors must increase. More attention should be given to thermal regulation, nutrition and management of infection in the survivors, before a more marked effect of surfactant can be seen.

Original languageEnglish (US)
Pages (from-to)280-287
Number of pages8
JournalJournal of Perinatal Medicine
Volume25
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Hyaline Membrane Disease
Latin America
Surface-Active Agents
Newborn Infant
Morbidity
Survival
Survivors
Bronchopulmonary Dysplasia
Pulmonary Emphysema
Necrotizing Enterocolitis
Patent Ductus Arteriosus
Infant Mortality
Therapeutics
Infection
Birth Weight
Hot Temperature
Confidence Intervals
Hemorrhage
Lung
Mortality

Keywords

  • Hyaline membrane disease
  • Latin America
  • Newborn
  • Pulmonary surfactants

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Rossello, J. D., Hayward, P. E., Martell, M., Del Barco, M., Margotto, P., Grandzoto, J., ... Villanueva, D. (1997). Hyaline membrane disease (HMD) therapy in Latin America: Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. Journal of Perinatal Medicine, 25(3), 280-287.

Hyaline membrane disease (HMD) therapy in Latin America : Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. / Rossello, Jose Diaz; Hayward, Paul Estol; Martell, Miguel; Del Barco, Mario; Margotto, Paulo; Grandzoto, Jose; Bastida, Jaime; Pena, Jose L.; Villanueva, Dina.

In: Journal of Perinatal Medicine, Vol. 25, No. 3, 1997, p. 280-287.

Research output: Contribution to journalArticle

Rossello, JD, Hayward, PE, Martell, M, Del Barco, M, Margotto, P, Grandzoto, J, Bastida, J, Pena, JL & Villanueva, D 1997, 'Hyaline membrane disease (HMD) therapy in Latin America: Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources', Journal of Perinatal Medicine, vol. 25, no. 3, pp. 280-287.
Rossello, Jose Diaz ; Hayward, Paul Estol ; Martell, Miguel ; Del Barco, Mario ; Margotto, Paulo ; Grandzoto, Jose ; Bastida, Jaime ; Pena, Jose L. ; Villanueva, Dina. / Hyaline membrane disease (HMD) therapy in Latin America : Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. In: Journal of Perinatal Medicine. 1997 ; Vol. 25, No. 3. pp. 280-287.
@article{bdfca93bbeb0402a9fcc32d95797974e,
title = "Hyaline membrane disease (HMD) therapy in Latin America: Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources",
abstract = "Impact of surfactant administration, on neonatal mortality, morbidity and resource use, was assayed in a historically controlled study in 19 NICUs from 5 Latin American countries. Data from clinical records of infants with HMD were retrospectively reviewed for the previous 2 years (PRE phase n = 666 cases), and prospectively in cases that received surfactant (SURF phase, 348 cases). Birth weight stratified relative risk, with 95{\%} confidence interval (RR ± 95{\%} CI) for death, in the SURF as compared to the PRE was 0.60 (0.49-0.74), 0.79 (0.68-0.92) and 0.82 (0.71-0.94), for days 7, 28 and at discharge, respectively. At all ages mortality was significantly lower during SURF. Significant increases were observed in the occurrence of pulmonary interstitial emphysema, pulmonary hemorrhage, patent ductus arteriosus, bronchopulmonary dysplasia, intrahospital infection and necrotizing enterocolitis. Resource use increased significantly. It is concluded that the use of surfactant in the region is an important advance, and the efficacy of management of the late complications of the very premature and labile HMD survivors must increase. More attention should be given to thermal regulation, nutrition and management of infection in the survivors, before a more marked effect of surfactant can be seen.",
keywords = "Hyaline membrane disease, Latin America, Newborn, Pulmonary surfactants",
author = "Rossello, {Jose Diaz} and Hayward, {Paul Estol} and Miguel Martell and {Del Barco}, Mario and Paulo Margotto and Jose Grandzoto and Jaime Bastida and Pena, {Jose L.} and Dina Villanueva",
year = "1997",
language = "English (US)",
volume = "25",
pages = "280--287",
journal = "Journal of Perinatal Medicine",
issn = "0300-5577",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "3",

}

TY - JOUR

T1 - Hyaline membrane disease (HMD) therapy in Latin America

T2 - Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources

AU - Rossello, Jose Diaz

AU - Hayward, Paul Estol

AU - Martell, Miguel

AU - Del Barco, Mario

AU - Margotto, Paulo

AU - Grandzoto, Jose

AU - Bastida, Jaime

AU - Pena, Jose L.

AU - Villanueva, Dina

PY - 1997

Y1 - 1997

N2 - Impact of surfactant administration, on neonatal mortality, morbidity and resource use, was assayed in a historically controlled study in 19 NICUs from 5 Latin American countries. Data from clinical records of infants with HMD were retrospectively reviewed for the previous 2 years (PRE phase n = 666 cases), and prospectively in cases that received surfactant (SURF phase, 348 cases). Birth weight stratified relative risk, with 95% confidence interval (RR ± 95% CI) for death, in the SURF as compared to the PRE was 0.60 (0.49-0.74), 0.79 (0.68-0.92) and 0.82 (0.71-0.94), for days 7, 28 and at discharge, respectively. At all ages mortality was significantly lower during SURF. Significant increases were observed in the occurrence of pulmonary interstitial emphysema, pulmonary hemorrhage, patent ductus arteriosus, bronchopulmonary dysplasia, intrahospital infection and necrotizing enterocolitis. Resource use increased significantly. It is concluded that the use of surfactant in the region is an important advance, and the efficacy of management of the late complications of the very premature and labile HMD survivors must increase. More attention should be given to thermal regulation, nutrition and management of infection in the survivors, before a more marked effect of surfactant can be seen.

AB - Impact of surfactant administration, on neonatal mortality, morbidity and resource use, was assayed in a historically controlled study in 19 NICUs from 5 Latin American countries. Data from clinical records of infants with HMD were retrospectively reviewed for the previous 2 years (PRE phase n = 666 cases), and prospectively in cases that received surfactant (SURF phase, 348 cases). Birth weight stratified relative risk, with 95% confidence interval (RR ± 95% CI) for death, in the SURF as compared to the PRE was 0.60 (0.49-0.74), 0.79 (0.68-0.92) and 0.82 (0.71-0.94), for days 7, 28 and at discharge, respectively. At all ages mortality was significantly lower during SURF. Significant increases were observed in the occurrence of pulmonary interstitial emphysema, pulmonary hemorrhage, patent ductus arteriosus, bronchopulmonary dysplasia, intrahospital infection and necrotizing enterocolitis. Resource use increased significantly. It is concluded that the use of surfactant in the region is an important advance, and the efficacy of management of the late complications of the very premature and labile HMD survivors must increase. More attention should be given to thermal regulation, nutrition and management of infection in the survivors, before a more marked effect of surfactant can be seen.

KW - Hyaline membrane disease

KW - Latin America

KW - Newborn

KW - Pulmonary surfactants

UR - http://www.scopus.com/inward/record.url?scp=1842287945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842287945&partnerID=8YFLogxK

M3 - Article

C2 - 9288665

AN - SCOPUS:1842287945

VL - 25

SP - 280

EP - 287

JO - Journal of Perinatal Medicine

JF - Journal of Perinatal Medicine

SN - 0300-5577

IS - 3

ER -